Raymond James Initiates Coverage On Lexeo Therapeutics with Strong Buy Rating, Announces Price Target of $25

Benzinga · 2d ago
Raymond James analyst Christopher Raymond initiates coverage on Lexeo Therapeutics (NASDAQ:LXEO) with a Strong Buy rating and announces Price Target of $25.